Page last updated: 2024-11-03

proglumetacin and Obesity

proglumetacin has been researched along with Obesity in 1 studies

proglumetacin : A carboxylic ester obtained by formal condensation of the carboxy group of indometacin with the hydroxy group of 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl N(2)-benzoyl-N,N-dipropyl-alpha-glutaminate. Used (as its dimaleate salt) to control pain and inflammation associated with musculoskeletal and joint disorders. Following oral administration, it is metabolised to indometacin and proglumide, a drug with antisecretory effects that helps prevent injury to the stomach lining.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Twenty-nine patients with gouty arthritis, rheumatoid arthritis and osteoarthritis were treated as outpatients with proglumetacin, at different doses, during 5-30 days."3.66[Proglumetacin for a wide spectrum of activity in clinical medicine]. ( Fossaluzza, V, 1983)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fossaluzza, V1

Other Studies

1 other study available for proglumetacin and Obesity

ArticleYear
[Proglumetacin for a wide spectrum of activity in clinical medicine].
    Minerva medica, 1983, Jun-23, Volume: 74, Issue:26

    Topics: Adult; Aged; Arthritis, Rheumatoid; Diabetes Complications; Drug Tolerance; Female; Gout; Humans; In

1983